Skip to content
Saturday, November 7, 2026
Explore the stories behind London's iconic bridges and hidd…

Giving Pluripotent Cells in Utero to Infants with Spina Bifida Enhances Quality of Life, Study Reveals

A pioneering research effort has discovered that delivering regenerative cells to developing infants diagnosed with spina bifida during corrective surgery could constitute a "important advancement" in treating birth defects.

Study Parameters and Security

The US-based trial examined six unborn babies with the 'open' form of spina bifida. Medical teams placed placenta-derived mesenchymal stem cells to the surface of the baby's spinal cord during the repair procedure.

Critically, the regenerative treatment demonstrated a favorable safety profile. Doctors verified that the cells did not cause tumors, interfere with wound healing, or prevent the reversal of co-occurring hindbrain herniation.

Positive Developments

Imaging conducted after delivery indicated a full resolution of brainstem displacement in each of the babies. This neurological improvement is closely linked to better mobility and function.

"In the event it allows additional babies capable of walking who otherwise would not, then it would become their standard of care," commented the principal investigator. "The results are profoundly encouraging and open the door to a variety of prospective new treatments."

Future Implications and Hope

Independent medical specialists indicated that subsequent studies of these observed advantages could signal a "new era" in in-utero treatment. The possibility of ameliorating neurological damage occurring during fetal development is regarded as a paradigm-shifting aim.

Especially significant would be improvements in urogenital and gastrointestinal outcomes, which are typical difficulties for those diagnosed with this disorder.

Future Directions

While this initial trial involved a limited number of patients, its safety demonstration and positive signals offer a robust platform for expanded clinical research. The addition of cellular treatment with established fetal surgery techniques presents significant potential for changing life trajectories for future generations with myelomeningocele.

RR
About the author

Richard Rangel

A historian and London enthusiast who loves uncovering the city's secrets.

London Reel Bridge

Type to search articles.